Fourteen patients with uncomplicated essential hypertension and mild asthma were treated with Atenolol 50-125 mg/day for up to 8 months. Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), rate pressure index (RPI), stress testing time (STT) and peak expiratory flow rate (PEFR) were measured before, during and after stress testing (ST) before and during treatment. Atenolol significantly lowered HR, SBP, DBP and RPI. It prolonged STT and had no effect on PEFR. Furthermore, Atenolol did not worsen the patient's asthma except for one patient. The drug did not interfere with the bronchodilatation effect of salbutamol.
Atenolol can be used cautiously to treat hypertension in asthmatic patients under certain conditions.
Get full access to this article
View all access options for this article.
References
1.
Decalmer Pbs , et al: Beta-blockers and asthma. Brit Heart J40: 184-189, 1978.
2.
Ellis ME, et al: Cardioselectivity in asthmatic patients. Eur J Clin Pharmacol21: 173-176, 1981.
3.
McLeod AA, et al: Differentiation of hemodynamic humoral and metabolic responses to B, and B2 adrenergic stimulation in men using Atenolol and propranolol . Circulation67: 1076-1084, 1983 .
4.
Study group on exercise challenge, bronchoprovocation committee. American Academy of Allergy.Guidelines for the methodology of exercise challenge testing of asthmatics. J Allerg Clin Immunol64: 642-648, 1979.
Lehman EL, Abrera HJ: Non-parametrics. Holden-Day Inc, McGraw Hill, Intern Book Company, San Francisco, 1975.
7.
Tukey JW: Exploratory data analysis. Addison-Wesley Publ Co, Massachusetts, 1977.
8.
Mallion JM, et al: Interet de l'etude a l'effort chez normotendu et ches l'hypertendu des chifre de la pression arterielle. Arch Mal Coeur68: 1001-1009, 1975.
9.
Astrom H., Vallin H.: Effect of a new beta-adrenergic blocking agent i.c.i. 66082 on exercise hemodynamics and airway resistance in angina pectoris. Brit Heart J36: 1194-1200, 1974.
10.
Cruickshank JM: The clinical importance of cardioselectivity and lipophilicity in beta-blockers. Am Heart J100: 160-178, 1980.
11.
Amery A., et al: Relationship between blood level of Atenolol and pharmacologic effect. Clin Pharm Therap21: 691-699, 1977.
12.
Gribbin HR, et al: Bronchial and cardiac beta-adrenoceptor blockade. A comparison of Atenolol, Acebutol and Labetamol. Br J Clin Pharmacol12: 61-65, 1981.
13.
Taylor EA, Trembath PW, Warrington SJ: Influence of environmental temperature and humidity on bronchial responses during assessment of selectivity of beta-adrenoreceptor antagonists in man . Br J Clin Pharmac12: 201-209, 1981.
14.
Leenen Fhh, et al: Effects of cardioselective and non-selective beta-blockade on dynamic exercise performance in mildly hypertensive men. Clin Pharmacol Ther28: 12-21, 1980.
Mohsen Ibrahim, Ragaa Mossallam: Clinical evaluation of Atenolol in hypertensive patients. Circulation64: 368-379, 1981.
17.
Vilsvik JS, Schanning J.: Effect of Atenolol on ventilatory and cardiac function in asthma. Brit Med J2: 453-455, 1976.
18.
Freis ED, Materson BJ, Flamenbaum W.: Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension . Am J Med74: 1029-1041, 1983 .
19.
McNeill RS: Effect of a beta-adrenergic blocking agent - propranolol - on asthmatics. Lancet2: 1101-1107, 1964.
20.
Palmer Knv: Respiratory side effects of beta-blockers (letter). Br Med J1: 840, 1977.
